While multiple prognostic models have been developed, the indolent nature of the disease, median patient age, and associated confounding factors make survival analysis difficult. Across multiple analytical models, age (>65), increased β2 microglobulin, and organomegaly (hepatomegaly or splenomegaly) have been identified as poor prognostic factors (4) . Additional adverse factors include anemia, low albumin levels, hyperviscosity and presence of constitutional symptoms such as fever, night sweats, fatigue, and weight loss (5) . The free light chain (FLC) concentration shows significantly higher values in symptomatic WM patients. Additionally, the FLC concentration was higher in patients with increased β2 microglobulin, hypoalbulinemia and anemia (6, 7) . Small patient series showed a correlation between FLC, time to treatment and overall survival (6, 8) , but larger studies are needed to confirm these findings.
Another biological factor found to be associated with prognosis was the von Willebrand factor, which showed an increased level in poor prognosis cases.
In addition, von Willebrand factor concentration also was associated with the existence of a microenvironment that stimulates the growth and survival of tumor cells (i.e. increased BM microvessel density and VEGF) (9) .
Because of the heterogeneity of WM, several situations require treatment.
As currently defined, WM is heterogeneous and may include more than 1 type of B-cell lymphoma. A consensus panel agreed that initiation of therapy was appropriate for patients with constitutional symptoms, such as fever, night sweats or weight loss. The median survival ranges from 5 to more than 10 years depending on the series analyzed(10-13).
The existence of somatic hypermutation in WM indicates a role for antigenic stimulation in the development of WM (14) (15) (16) . The IgH variable region genes are commonly mutated and the VH3 gene is often used, suggesting antigen exposure and selection (14, 17) . Clonality studies have shown clonal IgH and IgL gene rearrangements. The IgH variable region is commonly mutated in WM, but intraclonal variation is usually absent and IgH switching usually does not occur (18, 19) .
Environmental and inherited factors may contribute to familial IgM-MGUS/WM clusters. Patients with monoclonal gammopathy of undetermined significance (MGUS) are at increased risk for progression to WM (20) . In a population-based study of 1384 individuals with MGUS, researchers showed an increased risk factor of 46 for developing WM (20) . The rate of progression from IgM-MGUS to WM was further noted to be 1.5%-2% per year (21) (22) (23) . While the development of WM is thought to be sporadic, there are a few studies demonstrating familial linkage and predisposition to the disease (2, (24) (25) (26) . Both familial clustering of WM and a notable increase (~10 fold) of IgM-MGUS frequency in first-degree relatives of WM patients is suggestive of familial risk (27) . Using the assumption that WM and IgM-MGUS share common susceptibility genes, strong linkages involving chromosomes 1q, 3q, and 4q have been identified (21) . A causal relationship between MGUS/WM and chronic 6 antigenic stimulation has been suggested by the results of several studies (14-16, 28, 29) . Recently, it was shown that 11% of WM/IgM-MGUS reacted with paratarg-7 (P-7), a protein of unknown function (30) . Family analyses of relatives of patients with IgM MGUS/WM with an anti-P-7-paraprotein showed that the hyperphosphorylated state of this protein (pP7) is inherited as a dominant trait (30) . Because only 2.0% of healthy controls reacted against P-7, carriers of pP7 are associated with a >6 times increased risk of developing MGUS/WM (P = 0.001). Thus, pP-7 is the first molecularly characterized structure that provides a 
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Genetics studies
The low rate of proliferation of malignant WM cells was historically a major obstacle in the study of the genetic basis of WM, only surpassed in the last years with the incorporation of techniques focused on the study of interphase nuclei.
The conventional cytogenetics (CC) approach provided the first insights in whole genome analysis of WM (32, 33) . However the low resolution of the technique 
Practical aspects of genetic testing
Comprehensive, high-resolution tests are very powerful techniques in the analysis of WM genetics. They provide a complete analysis at DNA (aCGH/SNP arrays, sequencing), RNA (GEP, QPCR, sequencing) or microRNA level (microRNA array). Nevertheless, some points need to be considered before its incorporation in the analysis. A critical point to be highlighted is that only tumor cells must be analyzed when the molecular tests are performed in WM, in order 8 to avoid false negative results as a consequence of the contamination with nontumor cells. In order to obtain reliable data in any of these techniques, the tests must be performed in purified tumor cells by sorting or immunomagnetic beads.
The immuno-phenotype of WM consists of expression of pan-B-cell markers (CD19, CD20, CD22), cytoplasmic immunoglobulin (cIg), FMC7, CD38, and CD79a (31, 34, 35) . The number of plasma cells in patients with WM is generally in the normal range, but these plasma cells differ from normal and myeloma cells because although they are positive for CD38, they also commonly express CD19, CD45, and CD20, but lack CD56 (34) . With that in mind, a multiparametric sorting approach should be considered when a highly purified clonal population is required. The major limitations of this approach are the low number of cells obtained for further molecular studies (see below) and the complexity of the approach, which is not available in all laboratories. A more conservative strategy in order to collect all tumor cells would be to perform a serial enrichment using anti-CD19 and subsequently anti-CD138 beads.
Importantly, CD19 and CD138 markers are expressed in normal B cell lymphocytes and plasma cells, respectively. Thus, by using these cell surface markers both, normal and malignant cell populations will be enriched together.
To note, most of the molecular techniques can deal with moderate levels of contamination with non-tumoral cells (~20-30%), but when that threshold is surpassed the molecular results might be compromised. In FISH analysis, tumor must be either sorted or identified using FISH in combination with immunoflourescence detection of cytoplasmic immunoglobulin M (e.g. cIgM-FISH) (36) .
Another limiting factor for the high-throughput approaches is the requirement of a minimum number of tumor cells for DNA or RNA extraction.
Even though the amount of material needed for molecular testes varies between techniques, a minimum of 1-3 ug of DNA/RNA from tumor-enriched cells is desirable for most of the approaches. Unfortunately a significant fraction of patients are excluded in this point because of the low amount of DNA/RNA recovered. Finally, the recovered molecules must meet minimum quality requirements, especially when RNA studies are planned. Thus, RNA integrity number higher than 7.5 is required for array-based and next-generation sequencing techniques. Regarding DNA, a 260/280 ratio of 1.75-1.85 and 260/230 ratio higher than 1.9 is desirable for molecular testes.
Cytogenetics and FISH
Initial cytogenetic studies reported chromosomal abnormalities in around 10-20% of patients with WM, spanning observations from t(14;18) to trisomy 12 to deletion of 6q (32, 37) . Earlier CC analyses determined the deletion of 6q to be the most common, recurrent chromosomal abnormality identified in ~50% of patients(37). Schop et al. observed 23% of patients with an abnormal karyotype to have a 6q deletion, while FISH analysis confirmed deletion of 6q in 42% of patients (32) . Further studies used FISH analysis to assess minimal areas of deletion using multiple probes on the 6q arm and a minimal deleted region at 6q23-24.3 was suggested (38) .
In the most comprehensive cytogenetic study to date, Nguyen-Khan et al. each (39) . IgH rearrangements were only found in 3% of cases.
Although the deletion of 6q is present in around 50% of WM patients, its presence cannot be used for diagnosis as it is widely observed in several B-cell malignancies such as marginal zone lymphomas, multiple myeloma and chronic lymphocytic leukemias (40) (41) (42) (43) . On the other hand, data from CC and FISH analyses has consistently indicated that translocations of immunoglobulin heavy chain (IgH) are infrequently detected in WM. While prevalent in many other Bcell neoplasms such as MM, translocations involving IgH are very rare in WM (<3%) (38, 39, 44, 45) .
Most of the other recurrent chromosomal abnormalities observed in WM are shared with other low-grade B-cell neoplasms (trisomies 3 and 18 and deletions of 7q and 11q), such as MZL and CLL (40, 46) . Conversely, trisomy 4, which is identified in 10-20% of WM, seems to be unique in WM across low-grade B-cell neoplasias (40, 47) . Moreover, trisomy 4 has occasionally been found to be the sole genetic abnormality within a patient (45, 46) . Further analyses have not been able to identify a minimal gained region of chromosome 4, even using high-resolution approaches.
The presence of 6q deletion may have prognostic significance, although there are some controversies. Nguyen-Khan et al. found that patients with 6q deletion more frequently had albumin < 3.5g/dl (P = 0.005) and B2m > 3 mg/l (P = 0.04) and an associated longer time to progression (P = 0.04) in responding patients. Trisomy 4 had significantly more frequently b2 microglobulin > 3 mg/l (P = 0.02). Finally, TP53 deletion was associated with a shorter time to progression (P = 0.0007) in a multivariate analysis(39). Ocio et al. analyzed the status of 6q by FISH on 98 WM patients (48) . They found that patients with deletion 6q had higher B2M levels than patients without deletion 6q (>40 mg/l: 52% vs. 14% of case respectively, P = 0.001), anemia (Hb <110 g/l in 66% vs. 40%, P = 0.01) and lower albumin (< 40 g/l in 90% vs. 54%, P = 0.001). In others studies patients with a 6q deletion have been reported to have lower IgM production than those without, yet significant correlations between 6q deletions, disease progression, or prognosis for WM patients were not shown (49, 50) .
While the clinical implications of trisomy 4 are not well understood, it has been suggested that 4q may play a role in increased susceptibility to WM (21) . In a genome-wide linkage analysis consisting of 122 individuals from 11 families identified as high-risk for WM, high nonparametric linkage was found on cytoband 4q33-q34, suggesting both linkage and common susceptibility between IgM-MGUS and WM patients (21) . The results of this single study lay the groundwork for further study of chromosome 4 and the potential role it plays in the etiology of WM.
Array-based comparative genomic hybridization (aCGH)
The use of aCGH has increased the depth of our knowledge about chromosomal abnormalities seen in WM. A study including 42 patients concluded 83% of cases had chromosomal abnormalities, with a median of 3 abnormalities per case (46) . Overall, 16 copy-number changes were found in >5% of patients ( Figure 2) . As previously noted, partial or whole deletion of 6q proves to be the most commonly observed chromosomal abnormality. The loss of four separate minimal deleted regions (MDR) in 6q has been seen across several B-cell neoplasms. Of note, two of these MDR in WM include PRDM1 (BLIMP) and TNFAIP3, respectively (46) . PRDM1 is well known for its repression of cell proliferation genes and also down-regulates PAX5 that in turn suppresses XBP1. While PAX5 has not been found to be mutated or overexpressed in WM, XBP1 has been shown to be overexpressed in a subset of WM patients (61%) by quantitative RT-PCR(51). TNFAIP3 is a tumor suppressor gene and its inactivation results in the constitutive activation of the NF-κB signaling pathways (Table 1) In addition to IL-6, CD1c was upregulated in GEP studies (71) . While also expressed in normal B cells, upregulation of CD1c was significantly higher in WM than in MM or CLL and was proposed to be a potential disease marker (71) . The relatedness between these disease expressions suggests that IGM-MGUS precedes WM (71) . Through GEP, differences and similarities between WM and other B-cell neoplasias can be further extrapolated and perhaps used as disease markers.
Proteomics Analysis
Proteomic analyses in WM are still limited to small studies. In an analysis performed in 10 WM cases, 6 polypeptides, all of which regulate signal transduction, were found to be dysregulated (>2-fold) in >60% of cases (76) .
Interestingly, Ras family proteins, including p62Dok and Rab4 were upregulated (Table 3) . This increase correlated with the activation of MAPK pathways previously recognized in WM. Rho family protein levels were also found to be elevated, suggestive of an increase in adhesive properties of malignant WM cells (76) . Using a lower cutoff (>1.3-fold), a much larger number of dysregulated proteins were identified. Notably, cyclin-dependent kinases, regulators of apoptosis, HDAC, and proteins involved in the PI3 Kinase pathway were all upregulated. The cumulative effect of this protein dysregulation leads to loss of cell cycle restriction, increased cell survival, and proliferation. The upregulation of the above proteins was found in both symptomatic and asymptomatic patients, indicating that this deregulation occurs early within disease pathogenesis(76).
Symptomatic disease progression was marked in this study by three proteins:
p43/EMAPII, CDC25c, and HSP90. Each of these proteins furthers the disease's advancement, replication and migration.
Dysregulated Molecular Pathways
PI3K/Akt/mTOR
The PI3/Akt pathway regulates cell survival, increasing proliferation while inhibiting apoptosis (77) . Furthermore, Akt activity increases cell migration and adhesion (78) (79) (80) . Several studies have found increased Akt expression in WM (78, 81) . This is concordant with findings of elevated expression of PI3K pathway proteins (76) . While not unique to WM (Akt expression is also increased in MM), constitutive activation results in cell resistance by maintaining cell cycle pathways, inhibiting apoptosis, and supporting proliferation and cell survival (81) .
Both IL-6 and IGF-1 activate Akt pathways and provide strong targets for therapy (78) . Recently it was suggested that PTEN negatively regulates this pathway (81) . In WM, though no mutation has been observed, PTEN gene and protein expression were found to be decreased, and it was suggested that low levels of PTEN lead to consistent activation of the PI3K/Akt pathway(81).
Additionally, PTEN acts to negatively regulate mTOR, which like Akt, has increased activation due to phosphorylation in WM. Importantly, these pathways also provide targets for specific therapies (Figure 3) . The first-generation mTOR inhibitors rapamycin and its analogue everolimus employ an allosteric mechanism to block mTORC1 output (82) . A phase II trial using everolimus as a single-agent therapy on relapsed/refractory WM patients showed high activity,
with an overall response rate of 70% and a moderate toxicity (83) . In contrast, second mTOR inhibitors target the ATP binding site to impede kinase activity of both mTORC1 and mTORC2 (Figure 3 
)(82).
Another promising inhibitor is NVPBEZ235, which targets both, Akt and mTOR pathways, successfully reversing the activation of and dually inhibiting these overactive pathways (81) . These studies provide encouraging data for utilizing individualized treatment to target overactive pathways in WM.
JAK/STAT
The Akt/PI3K pathway is upregulated when STAT5 proteins are elevated (84) . The JAK/Stat pathway is a critical cytokine-initiated cascade that utilizes several STAT proteins to achieve normal physiologic and biological function, including hematopoiesis(85). Loss of these receptors and second messenger functions can be fatal and has been shown to severely disrupt erythropoiesis and lymphoid development(85). When constitutively active, cells exhibit an increase in antiapoptotic genes, cell cycle progression, and tumor evasion (74) . Each of these characteristics is noted in WM. JAK1 and STAT3, both of which are activated by IL-6, show increased expression in WM, despite no known mutations in their respective genes (74) . The continuous study of these dysfunctional pathways in WM will help provide targeted therapies.
Microenvironment -WM tumor cell interactions
Ngo et al. showed that WM cells express high levels of chemokine and adhesion receptors, including CXCR4 and VLA-4(86). They showed that CXCR4
was essential for the migration of WM cells. Furthermore, CXCR4 knockdown or the CXCR4 inhibitor AMD3100 showed a significant inhibition of migration.
Likewise, CXCR4 or VLA-4 inhibition led to significant inhibition of adhesion to fibronectin, stromal cells, and endothelial cells (86) . Additionally, they showed that the CXCR4/SDF-1 axis interacts with VLA-4 in regulating migration and adhesion of WM cells in the bone marrow microenvironment. 
In vitro and in vivo models
Conclusions
The last decade has been of a marked evolution in our knowledge of the molecular basis of WM pathogenesis. Undoubtedly, the incorporation of highthroughput "omics" analyses to the study of WM has led to the discovery of a plethora of genetic abnormalities and molecular pathways associated with the disease. These powerful tools have identified novel biomarkers that might be used in the differential diagnosis and risk stratification of the disease. Certainly, the main challenge in the post-"omics" era is to find the potential "Achilles' heels" to be exploited for drug discovery and rapidly translate these insights into novel 
